Neuroendocrine prostate cancer

Cover Page

Cite item

Full Text

Abstract

In Russia, prostate cancer is a common disease with fast increasing incidence. In the vast majority of prostate cancer patients receiving hormone therapy, on average 18–36 months after the start of treatment refractoriness to androgen ablation develops. In 15–20 % of patients, signs of neuroendocrine differentiation may develop.
Neuroendocrine prostate cancer is an aggressive variant of castration-resistant prostate cancer with poor prognosis and low survival.
Due to the rarity of these types of tumors, specific diagnostic and treatment algorithms have not been developed. As a rule, they are similar to the methods for other malignant forms of prostate cancer and neuroendocrine tumors.

About the authors

S. Z. Safina

Republican Clinical Oncology Dispensary of the Ministry of Health of the Tatarstan Republic named after prof. M.Z. Sigal

Email: 1967125@rambler.ru

29 Sibirskiy Trakt St., Kazan 420029, Russia 

Russian Federation

A. Z. Isyangulova

Republican Clinical Oncology Dispensary of the Ministry of Health of the Tatarstan Republic named after prof. M.Z. Sigal

Author for correspondence.
Email: a.isyangulova@rambler.ru
ORCID iD: 0000-0001-8570-9921
SPIN-code: 2245-6327

Alina Zulfatovna Isyangulova 

29 Sibirskiy Trakt St., Kazan 420029, Russia 

Russian Federation

References

  1. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  2. Aggarwal R., Zhang T., Small E.J., Armstrong A.J. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014;12(5):719–26. doi: 10.6004/jnccn.2014.0073
  3. Nagtegaal I.D., Odze R.D., Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76(2):182–8. doi: 10.1111/его.13975
  4. Zhang Q., Han Y., Zhang Y. et al. Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases. Front Oncol 2021;10:571308. doi: 10.3389/fonc.2020.571308
  5. Hirano D., Okada Y., Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45(5):586–92. doi: 10.1016/j.eururo.2003.11.032
  6. Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 2018;36(24):2492–503. doi: 10.1200/JCO.2017.77.6880
  7. Abida W., Cyrta J., Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 2019;116(23):11428–36. doi: 10.1073/pnas.1902651116
  8. Bluemn E.G., Coleman I.M., Lucas J.M. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 2017;32(4):474–89. doi: 10.1016/j.ccell.2017.09.003
  9. Beltran H., Prandi D., Mosquera J.M. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016;22(3):298–305. doi: 10.1038/nm.4045
  10. Umar S.A., Maclenna G.T. Small cell carcinoma of the prostate. J Urol 2009;181(2):838–9. doi: 10.1038/nrurol.2014.21
  11. Barcons L.A.L. Small cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model? Asian J Androl 2010;12(3):308–14. doi: 10.1038/aja.2009.68
  12. Beltran H., Tagawa S.T., Park K. et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. Clin Oncol 2012;30(36):386–9. doi: 10.1200/JCO.2011.41.5166
  13. Beltran H., Rickman D.S., Park K. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1(6):487–95. doi: 10.1158/2159-8290.CD-11-0130
  14. Hu C.D., Choo R., Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 2015;5:90. doi: 10.3389/fonc.2015.00090
  15. Patel G.K., Chugh N., Tripathi M. Neuroendocrine differentiation of prostate cancer-an intriguing example of tumor evolution at play. Cancers (Basel) 2019;11(10):1405. doi: 10.3390/cancers11101405
  16. Anichkov N.M., Plotnikova N.A. About morphology and classification of tumor-like and malignant prostatic lesions. Arkhiv patologii = Pathology Archive 2001;(5):44–50. (In Russ.).
  17. Zhang Y., Zheng D., Zhou T. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREBEZH2-TSP1 pathway in prostate cancers. Nat Commun 2018;9(1):4080. doi: 10.1038/s41467-018-06177-2
  18. Puca L., Vlachostergios P.J., Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med 2019;9(2):30593. doi: 10.1101/cshperspect.a030593
  19. Montironi R., Cimadamore A., Lopez-Beltran A. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells 2020;9(5):1073. doi: 10.3390/cells9051073
  20. Mahal B.A., Yang D.D., Wang N.Q. et al. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. Eur Urol 2018;74(2):146–54. doi: 10.1016/j.eururo.2018.01.043
  21. Wang J., Xu W., Mierxiati A. et al. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate 2019;79(13):1563–71. doi: 10.1002/pros.23878
  22. Helpap B., Kollermann J., Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 1999;62:133–8. doi: 10.1159/000030376
  23. Marcus D.M., Goodman M., Jani A.B. et al. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012;15(3):283–8. doi: 10.1038/pcan.2012.4
  24. Shimamura T., Kurauchi T., Sakanaka K. et al. Clinical investigation of neuroendocrine differentiation in prostate cancer. J Clin Oncol 2020;38:138. doi: 10.1200/jco.2020.38.6_suppl.138
  25. Hvamstad T., Jordal A., Hekmat N. et al. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003;44(2):215–6. doi: 10.1016/s0302-2838(03)00257-4
  26. Spetsieris N., Boukovala M., Patsakis G. et al. Neuroendocrine and aggressive-variant prostate cancer. Cancers (Basel) 2020;12(12):3792. doi: 10.3390/cancers12123792
  27. Apostolidis L., Nientiedt C., Winkler E.C. et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 2019;10(1):17–29. doi: 10.18632/oncotarget.26523
  28. Zhu J., Liang X., Wu D. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine (Baltimore) 2021;100(15):25237. doi: 10.1097/MD.0000000000025237
  29. Vlachostergios P.J., Papandreou C.N. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 2015;5:6. doi: 10.3389/fonc.2015.00006
  30. Papandreou C.N., Daliani D.D., Thall P.F. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20(14):3072–80. doi: 10.1200/JCO.2002.12.065
  31. Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844–8. doi: 10.1016/j.juro.2007.05.044
  32. Apostolidis L., Bergmann F., Jäger D., Winkler E.C. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med 2016;5(9):2261–7. doi: 10.1002/cam4.807
  33. Antonia S.J., Lopez-Martin J.A., Bendell J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17(70):883–95. doi: 10.1016/S1470-2045(16)30098-5
  34. Kaufman H.L., Russell J., Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17(10):1374–85. doi: 10.1016/S1470-2045(16)30364-3
  35. Nghiem P.T., Bhatia S., Lipson E.J. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016;374(26):2542–52. doi: 10.1056/NEJMoa1603702
  36. Ugwu J.K., Nwanyanwu C., Shelke A.R. Dramatic response of a metastatic primary small-cell carcinoma of the pancreas to a trial of immunotherapy with nivolumab: a case report. Case Rep Oncol 2017;10(2):720–5. doi: 10.1159/000479315
  37. Paraghamian S.E., Longoria T.C., Eskander R.N. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract 2017;4:3. doi: 10.1186/s40661-017-0038-9
  38. Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer 2019;121:7–18. doi: 10.1016/j.ejca.2019.08.011
  39. Wang Z.A., Toivanen R., Bergren S.K. et al. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep 2014;8(5):1339–46. doi: 10.1016/j.celrep.2014.08.002
  40. Mosca A., Berruti A., Russo L. et al. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005;28(11 Suppl):141–5.
  41. Komiya A., Suzuki H., Imamoto T. et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009:6(2):37–44. doi: 10.1111/j.1442-2042.2008.02175.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.